| Name | GSK-LSD1 Dihydrochloride |
|---|
| Description | GSK-LSD1 Dihydrochloride is a potent, selective and irreversible lysine specific demethylase 1 (LSD1) inhibitor with an IC50 of 16 nM. |
|---|---|
| Related Catalog | |
| Target |
IC50: 16 nM (LSD1)[1] |
| In Vitro | GSK-LSD1 Dihydrochloride shows more than 1000 fold selectivity over other closely related FAD utilizing enzymes including LSD2, and monoamine oxidases MAO-A, MAO-B[1]. GSK-LSD1 can inhibit KDM1A/LSD1 enzyme activity. GSK-LSD1 induces the formation of LC3-II in U2OS cells. The electronic microscopy shows the formation of autophagosome with GSK-LSD1 treatment. GSK-LSD1 potently inhibits proliferation of varies cancer cell lines by changing gene expression patterns[2]. |
| References |
| Molecular Formula | C14H22Cl2N2 |
|---|---|
| Molecular Weight | 289.24 |
| Storage condition | 2-8℃ |